1.	High-Dose Interferon alfa in Treating Patients With Stage II or Stage III Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-1697, SWOG-E1697, CALGB-500103, CAN-NCIC-ME10, COG-E1697, E1697, NCT00003641, ME10
2.	Complete Lymph Node Dissection or Observation in Treating Patients With Localized Melanoma and Sentinel Node Metastasis Who Have Undergone Sentinel Lymphadenectomy Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI Protocol IDs: JWCI-MORD-LM/SL-CLND-1102, NCT00389571
3.	Lovastatin in Treating Patients at High Risk of Recurrent Melanoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCIRVINE-UCI03-1-01, UCI03-1-01, UCIRVINE-2006-4937, NCT00462280
4.	Vaccine Therapy With or Without Montanide ISA-51 and/or Imiquimod in Treating Patients With Melanoma That Has Been Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: NCI Protocol IDs: NCI-06-C-0069, 7676, NCI-7676, NCI-P6703, NCT00304057
5.	Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
6.	Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: MEL06, NCT00539591
7.	Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-Risk Melanoma Patients Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 07.0008, NCT00553618
8.	Gene-Modified T Lymphocytes With or Without Vaccine Therapy and/or Aldesleukin in Treating Patients With High-Risk Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-08-C-0162, 08-C-0162, NCI-P07309, NCT00706992
9.	Abraxane and Temodar Plus Genasense in Advanced Melanoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GM108, NCT00409383
10.	Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-03740, NCT00580320
11.	Interferon alfa-2b in Treating Patients Who Have Undergone Surgery for High-Risk or Metastatic Melanoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 and over Sponsor: NCI Protocol IDs: OSU-07033, OSU 07033, OSU-2007C0057, NCT00634127
12.	Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ALS-357-001, NCT00701987
13.	A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2008_541, NCT00753415
14.	Randomized, Double Blind, Placebo-Controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NYU 05-409, NCT00821652
15.	Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0816, NCT00861406
16.	Effects of GM-CSF and/or Incomplete Freund's Adjuvant on Immune Cells at or Around the Tumor Site in Patients With Stage I or Stage II Melanoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Active Age: 18 to 85 Sponsor: NCI Protocol IDs: UVACC-MEL-38, UVACC-14499, UVACC-HIC-8380
17.	A Proof-of-Concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Phase: No phase specified Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GE-135-003, NCT00565721
18.	Vaccine Therapy in Treating Patients With Advanced Melanoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and older Sponsor: NCI Protocol IDs: UVACC-MEL-48, Mel 48, UVACC-IRB-13498, UVACC-PRC-450-07, NCT00705640
19.	Pilot Study of IFN a2b for Melanoma Patients Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-067, NCT00871533
20.	Comparison of Standard of Care or Treatment on Protocol Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INST 0813, NCT01010334